{"Symbol": "AARD", "AssetType": "Common Stock", "Name": "Aardvark Therapeutics, Inc. Common Stock", "Description": "Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The company is headquartered in San Diego, California.", "CIK": "None", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO, CA, UNITED STATES, 92122", "OfficialSite": "https://aardvarktherapeutics.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "263457000", "EBITDA": "-53437000", "PERatio": "None", "PEGRatio": "None", "BookValue": "5.63", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-2.53", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "-0.308", "ReturnOnEquityTTM": "-0.481", "RevenueTTM": "0", "GrossProfitTTM": "0", "DilutedEPSTTM": "-2.53", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "32.64", "AnalystRatingStrongBuy": "2", "AnalystRatingBuy": "10", "AnalystRatingHold": "0", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "-", "ForwardPE": "-", "PriceToSalesRatioTTM": "-", "PriceToBookRatio": "2.156", "EVToRevenue": "-", "EVToEBITDA": "-", "Beta": "None", "52WeekHigh": "19.58", "52WeekLow": "4.88", "50DayMovingAverage": "13.79", "200DayMovingAverage": "12.05", "SharesOutstanding": "21773300", "SharesFloat": "11102800", "PercentInsiders": "14.552", "PercentInstitutions": "60.446", "DividendDate": "None", "ExDividendDate": "None"}